DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
Key Details
- 1FDA cleared DeepHealth's Prostate Suite, an AI platform for prostate MRI workflows.
- 2Tool provides AI assistance for lesion detection, risk assessment, segmentation, and PI-RADS reporting.
- 3Compatible with 11 fusion biopsy systems, integrating with radiologists' existing tools.
- 4Real-world use: detected 27% more lesions, reduced segmentation variability by 65%, and cut biopsy workflow times by 37%.
- 5RadNet also received CE Mark in Europe for Brain Health, Brain Age, and LumbarMR AI solutions.
- 6LumbarMR AI supports lumbar spine MRI analysis, added through Gleamer acquisition.
Why It Matters
FDA clearance signals increasing acceptance and integration of AI tools in radiology. These solutions may meaningfully improve cancer detection accuracy, workflow efficiency, and broader access to prostate and other disease screenings.
Source
Radiology Business
Related News
•AuntMinnie
Human-AI Collaboration Achieves 99.2% Sensitivity for PE Detection in CTPA
A large study confirms that combining radiologists with FDA-cleared AI significantly improves pulmonary embolism detection on CTPA.
•AuntMinnie
MRI-Based AI Model Accurately Subtypes Colorectal Cancer
A machine-learning MRI radiomics model shows high accuracy for preoperatively subtyping colorectal cancer, potentially enabling improved treatment planning.
•Radiology Business
RadNet Bets Big on AI Integration for Unified Radiology Workflows
RadNet is heavily investing in DeepHealth to develop a comprehensive AI-driven radiology workflow platform.